Bioxytran, Inc is a clinical stage pharmaceutical company developing platform technologies in glycovirology hypoxia and degenerative diseases to eliminate viruses and prolong lifespan using carbohydrate drug design. The company was incorporated on June 9 2008 as America s Driving Ranges Inc and was reorganized into Bioxytran on September 21 2018 through a reverse merger to focus on the development manufacturing and commercialization of therapeutic drugs for hypoxia…
Bioxytran, Inc is a clinical stage pharmaceutical company developing platform technologies in glycovirology hypoxia and degenerative diseases to eliminate viruses and prolong lifespan using carbohydrate drug design. The company was incorporated on June 9 2008 as America s Driving Ranges Inc and was reorganized into Bioxytran on September 21 2018 through a reverse merger to focus on the development manufacturing and commercialization of therapeutic drugs for hypoxia degenerative diseases and antiviral treatment in humans. Its principal executive offices are located at 75 2nd Avenue Needham MA 02494.
The company expects to generate revenue from the sale of its therapeutic drug candidates once they receive regulatory approval and from licensing agreements with larger pharmaceutical partners. Revenue may also arise from collaborations and royalty arrangements related to its proprietary carbohydrate drug design and oxygen carrier platforms.
The company operates through the following segments.
• Pharmalectin Inc focuses on the development manufacture and commercialization of therapeutic drugs for viral diseases.
• NDPD Pharma Inc focuses on prototyping and development of specialized equipment for pharmaceutical manufacturing and on the development of carbohydrate molecules derived from partially hydrolyzed guar gum.
• Pharmalectin BVI Inc serves as custodian of the company s copyrights trademarks and patents.
• Pharmalectin India Pvt Ltd manages the company s local clinical research and trials and holds the local rights to commercialization in India.
Bioxytran occupies a niche position in the biopharmaceutical industry by focusing on carbohydrate based drug design for glycovirology and oxygen carrier therapeutics. The company s competitive advantages stem from its founder s decades of research on galectin proteins and its portfolio of issued patents that protect its platform technologies. While direct competitors are limited the company faces broader competition from other firms developing antiviral treatments and oxygen therapeutic agents.
The company intends to serve hospitals patients and healthcare providers that require antiviral treatments and oxygen therapeutic products. It also plans to partner with large pharmaceutical companies for licensing and distribution of its drug candidates. No specific customer names are disclosed in the filing.
Sector:HealthcareSector rationaleBioxytran is a clinical-stage pharmaceutical company developing therapeutic drugs for viral diseases, hypoxia, and degenerative diseases. Its revenue model is based on the future sale of drug candidates to hospitals and patients, as well as licensing agreements with pharmaceutical partners.Industry:BiotechnologyHealthcarePrimaryBioxytran is a clinical-stage company developing therapies derived from biological science, specifically focusing on carbohydrate drug design for glycovirology and oxygen carrier platforms. Its revenue model is based on the future sale of biologic drug candidates, licensing agreements, and royalties.Classified using BQ-MICSCIK: 0001445815